RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Innate Pharma - Stock

Innate Pharma Revenue 2024

Innate Pharma Revenue

35.66 M EUR

Ticker

IPH.PA

ISIN

FR0010331421

WKN

A0LCUJ

In 2024, Innate Pharma's sales reached 35.66 M EUR, a -31.29% difference from the 51.9 M EUR sales recorded in the previous year.

The Innate Pharma Revenue history

YEARREVENUE (undefined EUR)GROSS MARGIN (%)
2028e175.8427,89
2027e131.1137,41
2026e107.745,54
2025e73.466,82
2024e35.66137,54
202351.994,50
202249.5892,78
202112.1174,69
202056.1693,61
201968.9795,35
201879.8995,22
201732.6386,86
201656.1694,92
201517.9185,44
20140.91289,42
201312.4721,09
201210.388,57
20117.45-53,29
20100.21-4890,48
20093.31-305,14
20087.45-106,58
20078.69-81,47
20066.2-62,10
20051.3-326,15
20042.11-162,09

Innate Pharma Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Innate Pharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Innate Pharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Innate Pharma’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Innate Pharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Innate Pharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Innate Pharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Innate Pharma’s growth potential.

Innate Pharma Revenue, Profit, and EBIT History

DateInnate Pharma RevenueInnate Pharma EBITInnate Pharma Net Income
2028e175.84 M undefined38.05 M undefined0 undefined
2027e131.11 M undefined-25 M undefined0 undefined
2026e107.7 M undefined24.29 M undefined25.04 M undefined
2025e73.4 M undefined846,885 undefined2.45 M undefined
2024e35.66 M undefined-32.93 M undefined-28.39 M undefined
202351.9 M undefined-12.67 M undefined-7.57 M undefined
202249.58 M undefined-16.43 M undefined-58.1 M undefined
202112.11 M undefined-47.83 M undefined-52.81 M undefined
202056.16 M undefined1.08 M undefined-63.98 M undefined
201968.97 M undefined-27.05 M undefined-20.76 M undefined
201879.89 M undefined5.15 M undefined3.05 M undefined
201732.63 M undefined-39.98 M undefined-48.39 M undefined
201656.16 M undefined7.57 M undefined12.64 M undefined
201517.91 M undefined-10.77 M undefined-6.71 M undefined
2014907,000 undefined-19.97 M undefined-19.65 M undefined
201312.47 M undefined-2.79 M undefined-2.89 M undefined
201210.38 M undefined-3.39 M undefined-3.2 M undefined
20117.45 M undefined-7.57 M undefined-6.98 M undefined
2010210,000 undefined-13.69 M undefined-13.66 M undefined
20093.31 M undefined-15.54 M undefined-14.63 M undefined
20087.45 M undefined-11.01 M undefined-9.85 M undefined
20078.69 M undefined-9.09 M undefined-8.92 M undefined
20066.2 M undefined-7.24 M undefined-6.04 M undefined
20051.3 M undefined-6.42 M undefined-6.13 M undefined
20042.11 M undefined-5.02 M undefined-4.73 M undefined

Innate Pharma stock margins

The Innate Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Innate Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Innate Pharma.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Innate Pharma's sales revenue. A higher gross margin percentage indicates that the Innate Pharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Innate Pharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Innate Pharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Innate Pharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Innate Pharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Innate Pharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Innate Pharma Margin History

Innate Pharma Gross marginInnate Pharma Profit marginInnate Pharma EBIT marginInnate Pharma Profit margin
2028e94.5 %21.64 %0 %
2027e94.5 %-19.07 %0 %
2026e94.5 %22.55 %23.25 %
2025e94.5 %1.15 %3.34 %
2024e94.5 %-92.34 %-79.63 %
202394.5 %-24.41 %-14.59 %
202292.78 %-33.13 %-117.19 %
202174.69 %-394.86 %-436.01 %
202093.61 %1.92 %-113.94 %
201995.35 %-39.22 %-30.1 %
201895.22 %6.44 %3.82 %
201786.86 %-122.53 %-148.28 %
201694.92 %13.48 %22.51 %
201585.44 %-60.16 %-37.45 %
2014289.42 %-2,201.32 %-2,166.15 %
201321.09 %-22.37 %-23.18 %
20128.57 %-32.66 %-30.83 %
2011-53.29 %-101.61 %-93.69 %
2010-4,890.48 %-6,519.05 %-6,504.76 %
2009-305.14 %-469.49 %-441.99 %
2008-106.58 %-147.79 %-132.21 %
2007-81.47 %-104.6 %-102.65 %
2006-62.1 %-116.77 %-97.42 %
2005-326.15 %-493.85 %-471.54 %
2004-162.09 %-237.91 %-224.17 %

Innate Pharma Aktienanalyse

What does Innate Pharma do?

The company Innate Pharma SA is a biotechnology company that was founded in 1999 by immunologist Hervé Brailly. The company is headquartered in Marseille, France, and currently employs approximately 200 people. The business model of Innate Pharma is based on the research and development of immunotherapeutic drugs for various types of cancer and infectious diseases. The company leverages its expertise in the research and utilization of the so-called "innate immune system," which refers to the body's natural defense mechanisms against pathogens and cancer cells. Innate Pharma is active in various business sectors focusing on the development and marketing of therapeutic agents and products. These include: - Oncology: In the field of oncology, the company focuses on the development of drugs that specifically target cancer cells and inhibit cancer growth. Innate Pharma particularly emphasizes the research of antibodies that bind specifically to cancer cells and destroy them. An important product in this area is the medication Lumoxiti, used for the treatment of hairy cell leukemia. - Infectious diseases: In addition to cancer research, Innate Pharma also dedicates itself to the development of therapeutic agents against various infectious diseases. A significant focus here is on viral infections such as COVID-19. The company collaborates closely with various partners and research institutions to identify and develop promising agents. - Autoimmune diseases: Another business sector of Innate Pharma is the research and development of therapies for autoimmune diseases. The company primarily focuses on the use of antibodies and other proteins that aim to selectively influence the immune system and prevent misguided reactions of the body. Innate Pharma has developed and launched a variety of products in recent years. These primarily include therapeutic antibodies that specifically target various structures in the body and activate the body's immune defenses. An important product in this area is the monoclonal antibody IPH4102, used for the treatment of T-cell lymphoma. Innate Pharma collaborates closely with various partners and research institutions to identify and develop promising agents. These include large pharmaceutical companies such as Roche and Bristol-Myers Squibb, as well as innovative start-ups and university hospitals. The close collaboration with the research community aims to ensure that Innate Pharma remains at the forefront of progress and can quickly implement new developments. Like many biotechnology companies, research and development at Innate Pharma are very costly. To finance the development of new therapies, the company relies on cooperation with investors and the issuance of shares. In 2019, Innate Pharma generated a revenue of approximately 47 million euros and incurred a loss of about 55 million euros. However, the company is optimistic about achieving further successes in the coming years and expanding its position as a leading biotechnology company. Innate Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Innate Pharma's Sales Figures

The sales figures of Innate Pharma originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Innate Pharma’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Innate Pharma's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Innate Pharma’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Innate Pharma Stock

How much revenue did Innate Pharma generate this year?

Innate Pharma has achieved a revenue of 35.66 M EUR this year.

How much was the turnover of the company Innate Pharma compared to the previous year?

The revenue of Innate Pharma has increased by -31.29% decreased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Innate Pharma?

The revenue of Innate Pharma is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Innate Pharma measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Innate Pharma so important for investors?

The revenue of Innate Pharma is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Innate Pharma pay?

Over the past 12 months, Innate Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Innate Pharma is expected to pay a dividend of 0 EUR.

What is the dividend yield of Innate Pharma?

The current dividend yield of Innate Pharma is .

When does Innate Pharma pay dividends?

Innate Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Innate Pharma?

Innate Pharma paid dividends every year for the past 0 years.

What is the dividend of Innate Pharma?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Innate Pharma located?

Innate Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Innate Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Innate Pharma from 6/21/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 6/21/2024.

When did Innate Pharma pay the last dividend?

The last dividend was paid out on 6/21/2024.

What was the dividend of Innate Pharma in the year 2023?

In the year 2023, Innate Pharma distributed 0 EUR as dividends.

In which currency does Innate Pharma pay out the dividend?

The dividends of Innate Pharma are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Innate Pharma stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Innate Pharma

Our stock analysis for Innate Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Innate Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.